DGK Alpha Inhibitor Compounds for Selective T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can selectively inhibit diacylglycerol kinases (DGKalpha and DGKzeta) to restore T cell activation, enhance antitumor functionality, and overcome immune checkpoint suppression, particularly in the context of cancer and viral infections, while being safe and effective.
Innovation Solution
Development of compounds, or their pharmaceutically acceptable salts, that inhibit DGKalpha and/or DGKzeta, with specific structures defined by Formula (A) and (I)-(II), which can be administered to subjects to modulate DGK activity and enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to inhibit DGKalpha and DGKzeta, then T cell activation is restored and antitumor functionality is enhanced, but selectivity over other diacylglycerol kinases, protein kinases, and lipid kinases becomes difficult to achieve
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target unique regions or characteristics of DGKalpha and DGKzeta enzymes. The compounds contain specific molecular moieties that interact with distinctive residues or structural elements of these isoforms, allowing selective inhibition without affecting other kinase families. This is achieved through careful selection of R1, R2, R3, R4 substituents and core structural elements that match the binding pocket characteristics of DGKalpha/zeta specifically.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters of the inhibitor compounds including substituent types (R1-R4), linker lengths, ring structures, and stereochemical configurations. These parameter variations enable fine-tuning of binding affinity and selectivity for DGKalpha and DGKzeta versus other kinases. The structure-activity relationship studies guide optimization of these parameters to achieve the desired selectivity profile while maintaining inhibitory potency.
2Reliability
If compounds are developed to overcome immune checkpoint suppression, then immune response is enhanced, but safety and efficacy in clinical application become more challenging
Solution Approach 1:
The patent applies preliminary anti-action by designing compounds that preemptively counteract the suppressive effects of immune checkpoints before they can fully inhibit T cell function. The inhibitors work upstream in the signaling pathway by blocking DAG metabolism, thereby preventing the generation of signals that would lead to T cell exhaustion or suppression. This preliminary intervention restores T cell activation and enhances immune response before checkpoint-mediated suppression can take full effect, improving both efficacy and safety profile.
Data Source
AI summary
Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.